Promotion of tumor metastasis and chemoresistance via GDF15-GFRAL, NR5A2, p38 MAPK, and AKT/CREB1 pathways. Inhibition of immune response via NF-κB pathway and TAM activity. This evidence concerns the gene GFRAL and neoplasm.